#United States #Chicago #oncology #ASCO 2025 #Canopy

Canopy's Groundbreaking Role in Oncology at ASCO 2025

Canopy, a frontrunner in Enterprise AI for Oncology, is set to take center stage at the esteemed ASCO 2025 Quality Care Symposium, where it will present pivotal findings regarding its innovative Remote Therapeutic Monitoring (RTM) platform. This symposium, scheduled for October 10 at the Marriott Marquis in Chicago, is anticipated to draw significant attention from healthcare professionals and stakeholders alike.

Significance of the Study on Remote Therapeutic Monitoring

The study to be showcased focuses on the optimization of adherence to oral anti-cancer medications (OAM) among patients using Canopy's RTM system. Traditional management of OAM typically relies on phone calls, which can be time-consuming and often fail to capture the full spectrum of patients’ experiences. Canopy's EHR-integrated RTM platform, however, enhances the management process by offering scalable solutions that improve patient adherence and monitor potential toxicity.

Key Findings from the Research

The research revealed some impressive statistics regarding patient engagement and adherence to treatment. Over a period of three months, 1,857 patients engaged with the Canopy RTM platform, averaging seven reports each. Here are some of the most noteworthy findings:

• - Patient Engagement: 44% of participants reported no missed doses of their medication, indicating that a significant portion of patients adhered to their treatment plans effectively. However, 28.3% did report missing doses, largely due to forgetfulness or other clinical reasons. This statistic underscores the importance of proactive patient engagement strategies.
• - Symptom Management: The study also highlighted a correlation between symptom burden and missed doses, with common symptoms reported including weakness, fatigue, and pain. By identifying these issues, the Canopy platform allows healthcare providers to tailor their interventions more effectively.
• - Real-World Applications and Future Directions: Dr. Shruti Sharma, a leading researcher in the study, emphasizes that RTM offers vital insights into patients’ experiences between office visits. These insights can lead to earlier medical interventions and help close gaps in care, particularly for those in underserved areas.

Challenges and Opportunities in Oncology

Michael Kolodziej, MD, Chief Medical Officer at Canopy, noted the critical nature of meeting the ASCO and NCODA standards for oral anti-cancer medications. He articulated the challenges many practices face in capturing comprehensive patient data through traditional means. The transition to a more technology-driven approach, like RTM, enables better understanding and management of individual patient experiences, enhancing care quality significantly.

Previous Successes and Impacts

Canopy’s contributions to oncology have not gone unnoticed. Past data has indicated:

• - An impressive 45% improvement in treatment persistence over three months.
• - A marked 22% reduction in emergency room visits and hospital admissions per 100 patient months.
• - Sustained patient engagement figures of 88% at the six-month mark, indicating that patients find the platform beneficial.

The upcoming presentation at ASCO 2025 promises to reinforce the transformative power of Canopy’s solutions in oncology. As healthcare continues to evolve, the integration of digital health solutions like RTM will be essential for enhancing patient care and optimizing treatment outcomes.

About Canopy

Canopy stands at the intersection of healthcare and technology, providing innovative solutions that connect oncology practices with their patients. Its unified platform is pivotal in ensuring comprehensive care and support for patients throughout their treatment journeys. As a testament to its effectiveness, Canopy currently collaborates with a nationwide network of over 2,000 oncology providers.

For further updates on Canopy and its pioneering work in oncology, visit www.canopycare.us.